Drug and Device Advertising, Marketing & Promotion Legal Review

The advertising and promotion of pharmaceuticals and medical devices continues to evolve on both regulatory and technological fronts. Frier Levitt is in tune with these changes and counsels clients on the labeling, advertising, and promotion of FDA-regulated products.

Frier Levitt works with clients to launch new product designs, implementation, and promotion policies that ensure lawful First Amendment-protected dissemination and communication of information, in a fashion that is aligned with FDA thinking and safe harbors.

What We Do

Understanding current enforcement landscape, key regulatory considerations, and common pitfalls can help navigate the complexities of risk-based decision-making across a range of media. Our attorneys regularly advise on all issues relating to the Food and Drug Administration (FDA) regulations as well as counsel clients in matters arising under various statutes, including the Lanham Act and the Federal Trade Commission Act, as well as the so-called “little FTC Acts” implemented by the states and product-specific labeling laws. Frier Levitt attorneys continue to be involved in FTC investigations and enforcement proceedings relating to FDC, medical device and dietary supplements as well as health and environmental claims in advertising.

Frier Levitt attorneys are fluent in FDA advertising and promotional requirements, including claim support requirements, fair balance expectations, internet and social media challenges, adherence and preference programs, and disease state programs. We evaluate and apply the appropriate evidentiary standards that guide the review of different materials. We are particularly active in the developing area of food and dietary supplement advertising and labeling issues in the wake of statutory and regulatory changes brought about by the Nutrition Labeling and Education Act of 1990 and the Dietary Supplement Health Education Act of 1994. 

We are attuned to trends emerging from recent FDA Warning Letters and Untitled Letters in a post-Caronia world. We advise regularly regarding the complexities relevant to FDA Guidance’s such as the two FDA Guidance on off-label communications (Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities- Questions and Answers (June 2018); Medical Product Communications That Are Consistent With FDA-Required Labeling- Questions and Answers (Jan 2017). We provide comments for our clients on proposed regulatory guidance documents so they may inform agencies, for example, FTC’s “Guides Concerning the Use of Endorsements and Testimonials in Advertising.” We recognize current hot buttons such as emphasis on company Websites or increased enforcement coordination between the FDA and the DOJ (as evidenced by the Department of Justice’s (DOJ) recent scrutiny of patient-directed materials and recent False Claims Act settlements).

We represent clients in all matters involving advertising, marketing, intellectual property, and licensing.

Contact Us

For more information on Frier Levitt’s Advertising and Labeling capabilities, contact us today.